Skip to content
DataLookout
Menu

NCT04613440

FaCT Trial (Facilitated Cascade Testing Trial)

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words
    • Study completion pushed from Sep 18, 2026 to Dec 18, 2026
    • Publications: details revised at 1 of 1 entry
  2. Minor Trial status: Recruiting to Active, Not Recruitingv17 Show 4 more changesShow less
    • Enrollment target: estimated 820 to confirmed 524
    • Primary completion date changed from estimate of Mar 2026 to Sep 18, 2025
    • Study completion date: Dec 2026 to Sep 18, 2026
    • Site details revised at 3 of 3 sites
  3. Notable Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 3 of 3 sites
    v16
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v15
  5. Notable Primary completion date: Mar 2025 to Mar 2026v14
Show 12 earlier versionsHide 12 earlier versions
  1. Notable Primary completion date: Aug 2024 to Mar 2025
    • Enrollment target: 800 to 820
    • Study completion date: Aug 2025 to Dec 2026
    v13
  2. Minor Enrollment target: 660 to 800
    • Study description expanded, about 57 words
    • Site contacts updated at 1 of 3 sites
    v12
  3. Minor Site contacts updated at 1 of 3 sitesv11
  4. Notable Primary completion date: Mar 30, 2023 to Aug 2024v10 Show 4 more changesShow less
    • Enrollment target: 600 to 660
    • Study completion date: Nov 2023 to Aug 2025
    • Study description expanded, about 131 words
    • Study arms: 2 to 3
  5. Minor Site contacts updated at 1 of 3 sitesv9
  6. Minor Site contacts updated at 1 of 3 sitesv8
  7. Minor Primary completion date: Mar 2023 to Mar 30, 2023v7
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2021 to Jul 21, 2021
    • Site details revised at 3 of 3 sites
    v6
  9. Notable Start date: Mar 2021 to May 2021v5
  10. Minor Primary completion date: Feb 28, 2023 to Mar 2023
    • Study completion date: Nov 28, 2023 to Nov 2023
    • Start date: Feb 28, 2021 to Mar 2021
    v4
  11. Notable Start date: Nov 30, 2020 to Feb 28, 2021
    • Primary completion date: Nov 30, 2023 to Feb 28, 2023
    • Study completion date: Nov 30, 2023 to Nov 28, 2023
    v3
  12. Minor Site contacts updated at 1 of 3 sites
    • Study description expanded, about 1 word
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of genetic testing by 6 months among FDRs on each study arm
Timeframe: 6 months

Secondary (1)

Proportion of first-degree relatives who subsequently engage in recommended risk-reducing behaviors by 18 months

Arms and interventions

Standard of care - Proband-mediated cascade testingOther

Probands randomized to the standard of care group will be instructed to share a family letter (providing information on the familial mutation) with their FDRs and encourage FDRs to complete genetic testing.

Intervention - Facilitated cascade testingOther

In the intervention group, a patient navigator will provide facilitated support, including an initial genetic counseling call, an email with a link to an educational video, and, for individuals who are interested in completing testing - a link to create an account for a free saliva kit and a follow-up call to discuss the results and ensure participants are connected with their primary care provider or other clinician, as appropriate.

Exploratory ArmExperimental

Probands at WCM only who do not meet eligibility criteria for randomization to the intervention and control arms will be offered enrollment in a third arm, in which they will receive the intervention in addition to the option for referral to patient advocacy/support groups including FORCE: Facing Hereditary Cancer EMPOWERED, Sharsheret, SHARE, LatinaSHARE, Oneinforty, Susan G. Komen, Any Mountain, and Genetic Support Foundation, for additional guidance. Probands enrolled in this third arm only will be asked to share the names and contact information for all first, second, and third-degree relatives with whom they have shared their genetic testing results. We estimate enrolling up to 200 subjects into this exploratory third arm (50 probands and 150 Relatives including first, second, and third-degree relatives).

Other: Family Letter (Standard of Care), Educational Video, Mailed Saliva Kit for Genetic Testing, Telephone Counseling

Sites

3 sites in 1 country